

Chiara Ambrogio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9155200/publications.pdf>

Version: 2024-02-01

51
papers

3,468
citations

159585

30
h-index

197818

49
g-index

52
all docs

52
docs citations

52
times ranked

6285
citing authors

#	ARTICLE	IF	CITATIONS
1	The anaplastic lymphoma kinase in the pathogenesis of cancer. <i>Nature Reviews Cancer</i> , 2008, 8, 11-23.	28.4	792
2	KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS. <i>Cell</i> , 2018, 172, 857-868.e15.	28.9	220
3	Simple and Rapid In Vivo Generation of Chromosomal Rearrangements using CRISPR/Cas9 Technology. <i>Cell Reports</i> , 2014, 9, 1219-1227.	6.4	186
4	Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma. <i>Nature Medicine</i> , 2016, 22, 270-277.	30.7	150
5	Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. <i>Blood</i> , 2006, 107, 689-697.	1.4	127
6	The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. <i>Nature Medicine</i> , 2008, 14, 676-680.	30.7	112
7	Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C. <i>Cell Chemical Biology</i> , 2017, 24, 1005-1016.e3.	5.2	109
8	MT1-MMP Is Required for Myeloid Cell Fusion via Regulation of Rac1 Signaling. <i>Developmental Cell</i> , 2010, 18, 77-89.	7.0	108
9	Phosphatidylinositol 3-kinase $\hat{\imath}$ blockade increases genomic instability in B cells. <i>Nature</i> , 2017, 542, 489-493.	27.8	105
10	The Tyrosine Phosphatase Shp2 Interacts with NPM-ALK and Regulates Anaplastic Lymphoma Cell Growth and Migration. <i>Cancer Research</i> , 2007, 67, 4278-4286.	0.9	86
11	NPM-ALK Oncogenic Tyrosine Kinase Controls T-Cell Identity by Transcriptional Regulation and Epigenetic Silencing in Lymphoma Cells. <i>Cancer Research</i> , 2009, 69, 8611-8619.	0.9	86
12	A Braf kinase-inactive mutant induces lung adenocarcinoma. <i>Nature</i> , 2017, 548, 239-243.	27.8	85
13	Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 158-165.	7.0	81
14	p130Cas mediates the transforming properties of the anaplastic lymphoma kinase. <i>Blood</i> , 2005, 106, 3907-3916.	1.4	72
15	Human Wrnip1 Is Localized in Replication Factories in a Ubiquitin-binding Zinc Finger-dependent Manner. <i>Journal of Biological Chemistry</i> , 2008, 283, 35173-35185.	3.4	60
16	The Down syndrome critical region protein TTC3 inhibits neuronal differentiation via RhoA and Citron kinase. <i>Journal of Cell Science</i> , 2007, 120, 1859-1867.	2.0	59
17	Leukocyte transmigration is modulated by chemokine-mediated PI3K-dependent phosphorylation of vimentin. <i>European Journal of Immunology</i> , 2009, 39, 1136-1146.	2.9	59
18	Negative feedback regulation of Rac in leukocytes from mice expressing a constitutively active phosphatidylinositol 3-kinase $\hat{\imath}$ 3. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 14354-14359.	7.1	57

#	ARTICLE	IF	CITATIONS
19	Selective Therapeutic Targeting of the Anaplastic Lymphoma Kinase With Liposomal siRNA Induces Apoptosis and Inhibits Angiogenesis in Neuroblastoma. <i>Molecular Therapy</i> , 2011, 19, 2201-2212.	8.2	57
20	Wiskottâ€Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma. <i>Nature Medicine</i> , 2019, 25, 130-140.	30.7	57
21	The Anaplastic Lymphoma Kinase Controls Cell Shape and Growth of Anaplastic Large Cell Lymphoma through Cdc42 Activation. <i>Cancer Research</i> , 2008, 68, 8899-8907.	0.9	54
22	Increased <i>Rrm2</i> gene dosage reduces fragile site breakage and prolongs survival of ATR mutant mice. <i>Genes and Development</i> , 2015, 29, 690-695.	5.9	51
23	Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 4854-4864.	7.0	49
24	ALK-Dependent Control of Hypoxia-Inducible Factors Mediates Tumor Growth and Metastasis. <i>Cancer Research</i> , 2014, 74, 6094-6106.	0.9	45
25	Therapeutic inhibition of TRF 1 impairs the growth of p53-deficient Kâ€Ras ^{G12V} induced lung cancer by induction of telomeric DNA damage. <i>EMBO Molecular Medicine</i> , 2015, 7, 930-949.	6.9	45
26	Ground-glass nodules of the lung in never-smokers and smokers: clinical and genetic insights. <i>Translational Lung Cancer Research</i> , 2018, 7, 487-497.	2.8	45
27	Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex. <i>Neoplasia</i> , 2013, 15, 511-IN17.	5.3	44
28	A structural model of a Rasâ€Raf signalosome. <i>Nature Structural and Molecular Biology</i> , 2021, 28, 847-857.	8.2	44
29	Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors. <i>Cancer Immunology Research</i> , 2015, 3, 1333-1343.	3.4	42
30	Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency. <i>Oncogene</i> , 2016, 35, 3854-3865.	5.9	37
31	Modeling Lung Cancer Evolution and Preclinical Response by Orthotopic Mouse Allografts. <i>Cancer Research</i> , 2014, 74, 5978-5988.	0.9	30
32	An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib. <i>Journal of Thoracic Oncology</i> , 2018, 13, e131-e133.	1.1	30
33	KRASQ61H Preferentially Signals through MAPK in a RAF Dimer-Dependent Manner in Nonâ€Small Cell Lung Cancer. <i>Cancer Research</i> , 2020, 80, 3719-3731.	0.9	30
34	Redundant and nonredundant roles for Cdc42 and Rac1 in lymphomas developed in NPM-ALK transgenic mice. <i>Blood</i> , 2016, 127, 1297-1306.	1.4	26
35	Involvement of Grb2 Adaptor Protein in Nucleophosmin-Anaplastic Lymphoma Kinase (NPM-ALK)-mediated Signaling and Anaplastic Large Cell Lymphoma Growth. <i>Journal of Biological Chemistry</i> , 2010, 285, 26441-26450.	3.4	25
36	Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma. <i>Blood</i> , 2022, 139, 717-731.	1.4	22

#	ARTICLE	IF	CITATIONS
37	An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer. <i>EBioMedicine</i> , 2019, 49, 106-117.	6.1	20
38	PPP4R2 regulates neuronal cell differentiation and survival, functionally cooperating with SMN. <i>European Journal of Cell Biology</i> , 2012, 91, 662-674.	3.6	19
39	KRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapy. <i>ESMO Open</i> , 2016, 1, e000076.	4.5	19
40	Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1640-1650.	7.0	19
41	How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC). <i>Cancer Treatment Reviews</i> , 2022, 103, 102335.	7.7	19
42	ERK Inhibitor LY3214996-Based Treatment Strategies for RAS-Driven Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 641-654.	4.1	16
43	Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma. <i>JCI Insight</i> , 2020, 5, .	5.0	16
44	Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer. <i>Trends in Cancer</i> , 2021, 7, 410-429.	7.4	13
45	Expression of IFN γ R2 mutated in a dileucine internalization motif reinstates IFN γ signaling and apoptosis in human T lymphocytes. <i>Immunology Letters</i> , 2010, 134, 17-25.	2.5	12
46	Back to the Bench? MEK and ERK Inhibitors for the Treatment of KRAS Mutant Lung Adenocarcinoma. <i>Current Medicinal Chemistry</i> , 2018, 25, 558-574.	2.4	11
47	A putative role for Discoidin Domain Receptor 1 in cancer chemoresistance. <i>Cell Adhesion and Migration</i> , 2018, 12, 1-4.	2.7	9
48	Docking Protein p130Cas Regulates Acinar to Ductal Metaplasia During Pancreatic Adenocarcinoma Development and Pancreatitis. <i>Gastroenterology</i> , 2022, 162, 1242-1255.e11.	1.3	4
49	Discoveries in the redox regulation of KRAS. <i>International Journal of Biochemistry and Cell Biology</i> , 2021, 131, 105901.	2.8	2
50	A LIBRETTO to orchestrate targeted therapy. <i>Nature Cancer</i> , 2020, 1, 1038-1040.	13.2	1
51	DDR1 and Notch: a multifaceted synergy. <i>Translational Cancer Research</i> , 2016, 5, S1551-S1553.	1.0	0